inhibits doxorubicin-induced human umbilical vein endothelial cell death by modulating fas expression and via the PI3K/Akt pathway.
Trebananib is designed to bind to both angiopoietin-1
and -2 (Ang1 and Ang2), and inhibit their interaction with the Tie2 receptor.
, angiopoietin-2 and Tie-2 receptor expression in human dermal wound repair and scarring.
gene therapy for acute lung injury.
Additional blood-based proteins that are well cited in the literature as potential cancer biomarkers include haptoglobin-1 (increased in leukemia patients and associated with poor prognosis in small cell lung cancer); [alpha]-2-macroglobulin ([alpha]2M), a plasma proteinase inhibitor showing decreased expression in prostate cancer metastases (30); and angiopoietin-1
and -2 (Ang-1, Ang-2), increased levels have been observed in breast cancer.
Tie2 receptor ligands, angiopoietin-1
and angiopoietin-2, modulate VEGF-induced postnatal neovascularization.
Chemotactic properties of angiopoietin-1
and -2 ligands for the endothelial-specific receptor tyrosine kinase Tie-2.
Protective role of angiopoietin-1
in experimental pulmonary hypertension.
The enigmatic role of angiopoietin-1
in tumor angiogenesis.
(ANG-1) and angiopoietin-2 (ANG-2) must be in careful balance to maintain healthly endothelial cells that line blood vessels.
In addition, angiopoietin-1
produced by osteoblasts activates the stem cell receptor tyrosine kinase Tie2 and thereby promotes tight adhesion of stem cells to their niche (88).
1) Vascular endothelial growth factor (VEGF) and angiopoietin-1
(Ang-1) and angiopoietin-2 (Ang-2) are mediators of angiogenesis, and recent data suggest that the balance between these growth factors may affect vascular endothelial integrity.